×
About 32,700 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,887 results

Apathy is associated with parietal cortical-subcortical dysfunction in ALS.
https://doi.org/10.1016/j.cortex.2021.02.029
Cortex; a Journal Devoted to the Study of the Nervous Sys... Caga J, Tu S et. al.

Apr 19th, 2021 - Apathy is the core behavioural feature of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS). Initiation and emotional manifestations of apathy significantly affect patients and carers, particularly in terms of quality of life. As s...

Behavioural effects of cage systems on the G93A Superoxide Dismutase 1 transgenic mouse...
https://doi.org/10.1111/gbb.12735
Genes, Brain, and Behavior; Guerra S, Chung R et. al.

Apr 19th, 2021 - Environmental factors inherent to animal facilities can impact on the neuro-behavioural phenotype of laboratory mice and genetic mouse models for human diseases. Many facilities have upgraded from traditional 'open filter top' cages (FT) to indivi...

Epidemiological and genetic features of amyotrophic lateral sclerosis in Latin America ...
https://doi.org/10.1080/21678421.2021.1909066
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Erazo D, Luna J et. al.

Apr 19th, 2021 - Introduction: Heterogeneity of amyotrophic lateral sclerosis (ALS) has been suggested in terms of epidemiology, phenotypes and genetics between geographic areas and populations. However, there is limited information in Latin America. We conducted ...

A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sc...
https://doi.org/10.1093/brain/awab018
Brain : a Journal of Neurology; Freischmidt A, Goswami A et. al.

Apr 19th, 2021 - Knowledge about converging disease mechanisms in the heterogeneous syndrome amyotrophic lateral sclerosis (ALS) is rare, but may lead to therapies effective in most ALS cases. Previously, we identified serum microRNAs downregulated in familial ALS...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  16,297 results

Apathy is associated with parietal cortical-subcortical dysfunction in ALS.
https://doi.org/10.1016/j.cortex.2021.02.029
Cortex; a Journal Devoted to the Study of the Nervous Sys... Caga J, Tu S et. al.

Apr 19th, 2021 - Apathy is the core behavioural feature of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS). Initiation and emotional manifestations of apathy significantly affect patients and carers, particularly in terms of quality of life. As s...

Behavioural effects of cage systems on the G93A Superoxide Dismutase 1 transgenic mouse...
https://doi.org/10.1111/gbb.12735
Genes, Brain, and Behavior; Guerra S, Chung R et. al.

Apr 19th, 2021 - Environmental factors inherent to animal facilities can impact on the neuro-behavioural phenotype of laboratory mice and genetic mouse models for human diseases. Many facilities have upgraded from traditional 'open filter top' cages (FT) to indivi...

Epidemiological and genetic features of amyotrophic lateral sclerosis in Latin America ...
https://doi.org/10.1080/21678421.2021.1909066
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Erazo D, Luna J et. al.

Apr 19th, 2021 - Introduction: Heterogeneity of amyotrophic lateral sclerosis (ALS) has been suggested in terms of epidemiology, phenotypes and genetics between geographic areas and populations. However, there is limited information in Latin America. We conducted ...

A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sc...
https://doi.org/10.1093/brain/awab018
Brain : a Journal of Neurology; Freischmidt A, Goswami A et. al.

Apr 19th, 2021 - Knowledge about converging disease mechanisms in the heterogeneous syndrome amyotrophic lateral sclerosis (ALS) is rare, but may lead to therapies effective in most ALS cases. Previously, we identified serum microRNAs downregulated in familial ALS...

see more →

News  457 results

Theatrics, Hypnosis, and the Roots of Modern Neurology
https://www.medscape.com/viewarticle/947504

Mar 14th, 2021 - "Symptoms, then, are in reality nothing but a cry from suffering organs" – Jean-Martin Charcot Nearly 130 years after his death, Jean-Martin Charcot's name still resonates with modern neurologists. The famed 19th century French physician made myri...

New Compound Promising for ALS, Other Upper Motor Neuron Diseases
https://www.medscape.com/viewarticle/947056

Mar 10th, 2021 - NEW YORK (Reuters Health) - A new compound, NU-9, improved diseased upper motor neurons (UMN) in mice and shows promise for treating amyotrophic lateral sclerosis (ALS) in humans, though more work is needed before a clinical trial can be started, ...

After a Decade of Lobbying, ALS Patients Gain Faster Access to Disability Payments
https://www.medscape.com/viewarticle/944474

Jan 20th, 2021 - Anita Baron first noticed something was wrong in August 2018, when she began to drool. Her dentist chalked it up to a problem with her jaw. Then her speech became slurred. She managed to keep her company, which offers financing to small businesses...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.staging.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

see more →

Patient Education  19 results see all →